Johnson & Johnson Aktie: Pharma-Sparte übertrifft Erwartungen - Kursziel angehoben!
New York (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Morgan Stanley:
Morgan Stanley erhöht Kursziel auf 175 USD
Der Analyst Terence Flynn von…
£14,283
1,09%
Echtzeit-Aktienkurs Johnson Matthey PLC
Bid:
Ask:
Nachrichten zur Johnson Matthey PLC Aktie
ETFs in Focus Post JNJ Q3 Earnings Beat, Target Price Hike
Johnson & Johnson infused positive optimism after posting solid third-quarter 2024 earnings. A few analysts raised their target price on…
Verhaltene Kauflaune bei Johnson & Johnson-Aktie (151,4853 €)
Am US-amerikanischen Aktienmarkt ist der Anteilsschein von Johnson & Johnson aktuell unauffällig. Das Papier kostete zuletzt 164,46 US-Dollar. Kaum auffällig…
Johnson & Johnson Aktie: Solide Geschäftsfundamente - Kursziel angehoben!
St. Louis (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Stifel:
Stifel hat das Kursziel für Johnson & Johnson (ISIN: US4781601046, WKN: 853260,…
Johnson & Johnson Aktie: Optimistischer Ausblick für 2025 trotz verhaltener Q4-Wachstumsprognose
San Francisco (www.aktiencheck.de) - Johnson & Johnson-Aktienanalyse von Wells Fargo Advisors:
Wells Fargo hat das Kursziel für Johnson & Johnson (ISIN:…
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
JNJ earnings call for the period ending September 30, 2024.…
Johnson & Johnson (JNJ) Q3 2024 Earnings Call Transcript
…
Johnson & Johnson Q3: Strengthening Cardiovascular Device Portfolio
…
4 stocks to watch on Tuesday: BAC, JNJ and more
Bank of America (BAC), Goldman Sachs (GS), Johnson & Johnson (JNJ) and UnitedHealth (UNH) are the stocks to watch on…
Bank earnings, Nvidia record high, oil prices sink: 3 Things
US stock futures (ES=F, NQ=F, YM=F) are flat Tuesday morning coming off the Dow Jones Industrial Average (^DJI) and S&P…
J&J beats Q3 earnings estimates, raises full-year sales guidance
Johnson & Johnson (NYSE:JNJ) shares moved higher after the pharmaceutical giant posted better-than-expected results for the third quarter. Earnings per...…
Johnson & Johnson: Ergebnisprognose gekappt – das ist der Grund
Die Berichtssaison in den USA nimmt peu à peu an Fahrt auf. Traditionell gehört Johnson & Johnson neben den großen…
Johnson & Johnson reports Q3 beat, raises sales guidance By Investing.com
Johnson & Johnson reports Q3 beat, raises sales guidance…
United Health, Johnson & Johnson lead Tuesdays earnings lineup By Investing.com
United Health, Johnson & Johnson lead Tuesdays earnings lineup…
Cramers week ahead: Major banks, Taiwan Semi and Netflix report as earnings season gets into full swing
Charles Schwab, Bank of America, Johnson & Johnson, Walgreens, UnitedHealth Group Morgan Stanley, Procter & Gamble and Abbott Laboratories all…
J&J discontinues dengue drug study after changes in R&D portfolio
Johnson & Johnson said it will discontinue a mid-stage field study evaluating the efficacy of its experimental pill for the…
Johnson & Johnson discontinues dengue drug study By Reuters
Johnson & Johnson discontinues dengue drug study…
Wells Fargo says there is a risk that Johnson & Johnson will guide lower By Investing.com
Wells Fargo says there is a risk that Johnson & Johnson will guide lower…
Johnson & Johnson investing $2 billion in new manufacturing plant in Wilson, Cooper says
Johnson & Johnsons new facility will create 420 jobs in Wilson County.…
J&J to invest more than $2 billion in new manufacturing facility
Johnson & Johnson said on Tuesday it will invest more than $2 billion to build a new manufacturing facility at…
Johnson & Johnson-Aktie: Kurs nur geringfügig im Minus (144,7813 €)
Der Kurs der dem Anteilsschein von Johnson & Johnson kommt kaum von der Stelle. Der jüngste Kurs betrug 161,13 US-Dollar.…
2 Excellent Dividend Stocks to Buy With Less Than $200
Abbott Laboratories and Johnson & Johnson both have raised their dividends annually for more than 50 years.…
Johnson & Johnson: Wait For More Clarity (Rating Downgrade)
…
Is Johnson & Johnson Stock a Buy?
This healthcare blue chip is making all the right moves to reward shareholders.…
Johnson & Johnsons Rybrevant Scores Third FDA-Approval Of 2024 For Certain Type Of Inoperable Lung Cancer In Pretreated Patients
Thursday, the FDA approved Johnson & Johnson (NYSE:JNJ) Rybrevant (amivantamab-vmjw) in combination with standard-of-care chemotherapy (carboplatin and pemetrexed) for locally…
14:49: Johnson & Johnson: Aktie versucht auszubrechen
Papiere von Johnson & Johnson halten sich seit nunmehr einer Woche im Bereich eines seit April 2022 bestehenden Abwärtstrends auf…
Johnson & Johnson Aktie: Dividendenzahlung steht bevor
Die Johnson & Johnson Aktie zeigt sich in den letzten Tagen stabil und notiert aktuell bei 165,51 USD. Anleger blicken…
Johnson & Johnson: A Strategic MedTech Shift For This Dividend King
…
Chief Future Officer: Joseph Wolk, Johnson & Johnson CFO
Chief Financial Officers now play a critical role in shaping corporate strategy and positioning organizations to meet future challenges. Bloombergs…
How J&Js CFO Keeps His Footing on the Patent Cliff
Between 2024 and 2030, the largest US pharma companies will lose patent protections on drugs that now account for $180…
J&J CFO Sees Value in Tech Partnerships
Medical Technology has become a high-growth segment within the health care industry, while opening up new possibilities in patient care.…
12:28: Die meistgehandelten Produkte: Johnson & Johnson bietet Vergleich an!
Nach einer turbulenten Handelswoche zeigt der DAX® am Montag eine leichte Erholung, wobei er wieder über seine wichtigen 50- und…
Global Hematologic Malignancies Market Size To Worth USD 144.58 Billion By 2033 | CAGR Of 7.97%
The Global Hematologic Malignancies Market Size was Valued at USD 67.18 Billion in 2023 and the Worldwide Hematologic Malignancies Market…